Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-715 dose-ranging study in rheumatoid arthritis with background methotrexate
2004-002157-30Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tak-715 in rheumatoid arthritis (RA) (4 arms), sponsored by Takeda. Primary endpoints: ACR20 response rate at 6 weeks and Safety endpoints. Started Oct 2004; status: completed.
02
Drugs
tak-715
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-002157-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002157-30.